DrugDevX
Oncology clinical-development consultancy

Senior oncology clinical-development expertise, applied to the decision in front of you.

DrugDevX brings together experienced pharmaceutical and biotech professionals to help you set development strategy, interpret clinical data, identify development opportunities and risks, and oversee execution, from pre-IND through Phase 1-3 to post-approval lifecycle evidence.

Discuss your program Explore services
What the evidence looks like at each stage of oncology developmentFive panels along a development line: dose-finding curves before first-in-human, a response waterfall plot in Phase 1 to 2, time-to-event curves in Phase 3, a benefit-risk forest plot at filing and real-world evidence over the lifecycle. Schematic illustration; it contains no data.The evidence changes at every stageDose-findingResponseTime-to-eventBenefit–riskReal-worldPre-INDPhase 1–2Phase 3FilingLifecycleSchematic illustration. No data are shown.
  • Specialized in OncologyClinical development from first concept through lifecycle evidence.
  • Experienced Clinicians & Subject Matter ExpertsProfessionals with significant prior pharmaceutical and biotech experience.
  • Matched to the mandateFocused reviews, milestone projects and fractional leadership.
  • Confidential by arrangementMaterials are exchanged only through an agreed process.
Featured engagements

Leadership when you need it. Clarity when the data arrive.

Two key engagements that bring several of our capabilities together around a single outcome.

Fractional CMO Services

Senior medical leadership, scaled to your stage.

An experienced oncology clinician takes responsibility for clinical direction on an agreed part-time basis, with defined decision rights and a clear mandate.

  • Development strategyPlan, sequence, dose and endpoint decisions
  • GovernanceDecision rights, medical oversight and escalation
  • Team and providersDirection of the CRO, operations, data and monitoring
  • Board and executivesClinical content for boards, investors and partners
  • MilestonesFocused leadership at readouts, filings and transactions
Read about Fractional CMO Services
Clinical data review & communication

From first patient profile to the final data cut.

Physician-level review of oncology data, carried through interpretation and benefit–risk assessment into the narrative each audience needs.

  • Patient-level reviewChronology, exposure, safety and response, patient by patient
  • Efficacy and safetyStudy-level interpretation against the plan and the disease context
  • Benefit–riskA structured judgment with the uncertainty stated
  • Narrative and presentationMessages, figures and briefings for leadership, regulators and scientists
Read about clinical data review
Where we help

Three areas, one clinical point of view.

Strategy, execution and data interpretation belong together. Each area starts from a question your team is likely to be asking.

01

Strategy & Evidence

Development strategy, treatment landscape and asset assessment, protocol design and medical strategy, supported by senior clinical leadership.

  • Which indication and evidence path should we commit to?
  • What does a competitor’s readout change for us?
  • What does this asset’s evidence actually support?
Explore 6 services
02

Execution & Oversight

Trial design and protocol readiness, study start-up, conduct, regulatory interactions, with clear responsibilities between sponsor and providers.

  • Can our sites find and treat the patients the protocol needs?
  • Why is the CRO relationship not delivering?
  • Is our clinical position ready for an agency meeting?
Explore 6 services
03

Data, AI & Capability

Clinical data review and communication, data collection, document workflows, and carefully scoped AI and team-capability work.

  • What do these data mean, and how do we explain them?
  • Does our data collection support the review we need?
  • How should an AI-assisted tool be tested before we rely on it?
Explore 6 services
Start from your stage

Where is your program today?

Needs change as a program moves through development. Select a stage to see where we are usually asked to help.

Getting to a first study that can answer the right question

Choices about population, dose and operating model are hard to undo once a study is running. Senior clinical input is most valuable before they are made.

All services for this stage
First-in-human readinessSee the dependencies before the first patient.Development strategyChoose the development path your evidence can support.Fractional CMO ServicesSenior medical and clinical-development leadership, scaled to the stage of your company.

Planning the evidence that comes next

Clinicians keep asking questions after approval. A plan decides which to answer, with what evidence, and how the results are communicated.

All services for this stage
Medical affairs & evidencePlan the evidence clinicians will need after the pivotal data.Clinical data review & communicationFrom patient-level review to study-level conclusions, and the story your audience needs to hear.Competitive intelligenceWork out what a landscape change means for your program.
How we work

Advice that ends in a decision.

Consultancy Services fully tailored to your company's needs

01

Start with the decision.

We agree on the question, the audience and the deadline before choosing a method. The work should end in a decision, an action or a better-defined uncertainty.

02

Experienced people do the work.

DrugDevX brings together professionals with significant prior pharmaceutical and biotech experience. Senior practitioners do the analysis and the writing.

03

Specialists where the question needs them.

Biostatistics, regulatory, CMC, nonclinical, safety and data-management questions go to the right specialist, with responsibilities agreed at the start.

04

Evidence before opinion.

We separate what the data show from what we infer, and state the limits. Any AI-assisted work is scoped to a defined use and reviewed by qualified clinicians.

Disease areas

The oncology settings we support.

Development questions differ by tumor type. These are some of the disease areas where DrugDevX supports strategy, trial design, data interpretation and oversight.

Map of oncology disease areas by body regionA schematic body outline with six numbered markers: thoracic, gastrointestinal, head and neck, gynecologic, genitourinary, and central nervous system gliomas. Schematic illustration; it contains no data.631254Gliomas andglioblastomasHead and neckmalignanciesThoraciconcologyGastrointestinaloncologyGenitourinaryoncologyGynecologiconcology
1

Thoracic oncology

Biomarker-defined subsets, brain metastases and a fast-moving standard of care.

  • Non-small cell lung cancer
  • Small cell lung cancer
  • Mesothelioma
  • Thymic malignancies
2

Gastrointestinal oncology

Distinct biology by primary site, with biomarker selection and sequencing of therapy central.

  • Colorectal
  • Gastric and gastroesophageal junction
  • Esophageal
  • Hepatocellular and biliary tract
  • Pancreatic
3

Head and neck malignancies

Locoregional disease, combined-modality treatment, and the preservation of function.

  • Squamous cell carcinoma of the head and neck
  • Nasopharyngeal
  • Salivary gland
4

Gynecologic oncology

Platinum sensitivity, biomarker-defined groups and maintenance strategies shape trial design.

  • Ovarian
  • Endometrial
  • Cervical
5

Genitourinary oncology

Biomarker-selected cohorts, sequencing across many lines, and endpoints from response to radiographic progression-free survival.

  • Urothelial and bladder
  • Prostate
  • Renal cell
6

Low-grade Gliomas and Glioblastoma

Drug delivery across the blood–brain barrier, imaging-based response assessment and few effective options.

  • Glioblastoma (IDH-wildtype)
  • IDH-mutant astrocytoma and oligodendroglioma
  • Other diffuse gliomas
Perspectives

How we think about oncology development.

Short working notes on protocols, data, oversight and leadership.

Leadership

Fractional CMO leadership tailored to your specific needs

A practical way to define the mandate of a part-time chief medical officer before the engagement starts.

Read the perspective →Clinical data

Reading an oncology dataset from the patient upward

Why clinical data review, interpretation and communication belong together, and how to sequence them.

Read the perspective →Protocol design

Five questions before an oncology protocol is finalized

A short checklist for testing whether a protocol answers the clinical question and can be delivered.

Read the perspective →

All perspectives

Coverage

One oncology focus. The full clinical pathway.

Experience across oncology settings and modalities informs our approach to strategy, trial design, medical review and evidence interpretation.

Development stages

  • Pre-INDClinical strategy and development planning
  • Phase 1Early development and medical review
  • Phases 2–3Late development and trial execution
  • NDA / BLAClinical content for agency interactions and submissions
  • Post-marketingEvidence generation and real-world studies

Modalities

  • Targeted therapies and TKIs
  • Immuno-oncology
  • Hormone therapies
  • Monoclonal antibodies
  • Bispecific antibodies
  • T-cell engagers
  • Antibody–drug conjugates
  • Drug–device combinations

Who we support

  • Biotech companiesStrategy, fractional leadership and focused clinical support
  • Large pharmaceutical teamsSpecialist input on defined clinical questions
  • Investors and analystsClinical assessment of assets, evidence and risk
  • CROs and technology teamsClinical expertise for trial design, oversight and tools
In development

AI-assisted clinical review

DrugDevX is developing AI-assisted tools for clinical data review and document preparation. They are in development and are not offered as validated or production products.

Read about AI workflow advisory

  • Any pilot is limited to a defined use case and authorized data, under an agreed information-handling process.
  • Qualified clinicians review every output. The tools make no autonomous clinical decisions.
  • When we evaluate tools from others, we disclose our own interest first.
Start a conversation

Tell us about the decision in front of you.

A short, nonconfidential outline is enough: the development stage, the question and the timing. We will reply about fit, expertise and next steps.

Email DrugDevX Prepare an inquiry

Email links open your email application. Nothing is sent until you press send. Please do not include patient information or confidential study materials in a first message.

  1. 01
    Outline the needThe decision, the stage of the program and the timing.
  2. 02
    Establish fitExpertise, availability, relevant interests and information requirements.
  3. 03
    Agree the scopeDeliverables, responsibilities and commercial terms before work begins.